Safety of Tumour Necrosis Factor- Antagonists

Author： Khanna D.   McMahon M.   Furst D.E.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.5, 2004-01, pp. : 307-324

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumour necrosis factor antagonists

By Chantry D.  

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 5-13

Informa Healthcare

Access to resources Recommend Favorite

Tumour necrosis factor- antagonists and their therapeutic applications

By Lowe C.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 10, 1998-10 ,pp. : 1309-1322

Informa Healthcare

Access to resources Recommend Favorite

Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly: A Review of Their Efficacy and Safety

By Radovits Beáta J.   Kievit Wietske   Laan Roland F.J.M.  

Drugs & Aging, Vol. 26, Iss. 8, 2009-08 ,pp. : 647-664

Adis International

Access to resources Recommend Favorite

Tumour necrosis factor antagonists: Hodgkin's lymphoma: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1215, 2008-01 ,pp. : 39-39

Adis International

Access to resources Recommend Favorite

Immunomodulators/tumour necrosis factor antagonists: Naevi (first report with alefacept and etanercept): 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1111, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite